GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aoxing Pharmaceutical Co Inc (OTCPK:AOXG) » Definitions » Operating Income

Aoxing Pharmaceutical Co (Aoxing Pharmaceutical Co) Operating Income : $0.97 Mil (TTM As of Mar. 2017)


View and export this data going back to 2001. Start your Free Trial

What is Aoxing Pharmaceutical Co Operating Income?

Aoxing Pharmaceutical Co's Operating Income for the three months ended in Mar. 2017 was $0.88 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2017 was $0.97 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Aoxing Pharmaceutical Co's Operating Income for the three months ended in Mar. 2017 was $0.88 Mil. Aoxing Pharmaceutical Co's Revenue for the three months ended in Mar. 2017 was $5.70 Mil. Therefore, Aoxing Pharmaceutical Co's Operating Margin % for the quarter that ended in Mar. 2017 was 15.40%.

Aoxing Pharmaceutical Co's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aoxing Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2017 was 3.06%. Aoxing Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2017 was 10.70%.


Aoxing Pharmaceutical Co Operating Income Historical Data

The historical data trend for Aoxing Pharmaceutical Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aoxing Pharmaceutical Co Operating Income Chart

Aoxing Pharmaceutical Co Annual Data
Trend Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.15 -6.55 -3.34 8.70 6.23

Aoxing Pharmaceutical Co Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.53 -1.85 1.70 0.23 0.88

Aoxing Pharmaceutical Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aoxing Pharmaceutical Co  (OTCPK:AOXG) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Aoxing Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2017 is calculated as:

ROC % (Q: Mar. 2017 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2016 ) + Invested Capital (Q: Mar. 2017 ))/ count )
=3.512 * ( 1 - 51.85% )/( (53.675 + 56.844)/ 2 )
=1.691028/55.2595
=3.06 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2017) data.

2. Joel Greenblatt's definition of Return on Capital:

Aoxing Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2017 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2017 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2016  Q: Mar. 2017
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=3.512/( ( (24.066 + max(6.976, 0)) + (24.04 + max(10.593, 0)) )/ 2 )
=3.512/( ( 31.042 + 34.633 )/ 2 )
=3.512/32.8375
=10.70 %

where Working Capital is:

Working Capital(Q: Dec. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12.846 + 2.044 + 8.308) - (14.721 + 0.335 + 1.166)
=6.976

Working Capital(Q: Mar. 2017 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(14.505 + 2.406 + 10.03) - (14.79 + 0.262 + 1.296)
=10.593

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2017) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Aoxing Pharmaceutical Co's Operating Margin % for the quarter that ended in Mar. 2017 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2017 )/Revenue (Q: Mar. 2017 )
=0.878/5.702
=15.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Aoxing Pharmaceutical Co Operating Income Related Terms

Thank you for viewing the detailed overview of Aoxing Pharmaceutical Co's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Aoxing Pharmaceutical Co (Aoxing Pharmaceutical Co) Business Description

Traded in Other Exchanges
N/A
Address
624 Tyvola Road, Suite 103, No. 186, Charlotte, NC, USA, 28217
Aoxing Pharmaceutical Co Inc is a specialty pharmaceutical company. The company specializes in research, development, manufacturing, and distribution of a variety of narcotic, pain-management, and addiction treatment pharmaceutical products. Aoxing holds approximately 139 drug production certificates covering narcotic pain-management, exclusive prescription medicines, OTC and API products. It derives all its revenue from the People's Republic of China.
Executives
Wilfred Chow officer: Chief Financial Officer 30 WEST STREET, 3B, NEW YORK NY 10004
John P Oshea director C/O WESTMINSTER SECURITIES CORP, 100 WALL ST, 7TH FLOOR, NEW YORK NY 10005
John Leo director, officer: Secretary 80 WALL STREET, 5TH FLOOR, NEW YORK NY 10005

Aoxing Pharmaceutical Co (Aoxing Pharmaceutical Co) Headlines

No Headlines